Abstract:Inflammatory bowel diseases (IBDs) are chronic disorders involving dysregulated immune responses. Despite the role of disrupted host-microbial interaction in the pathophysiology of IBD, the underlying metabolic principles are not fully understood. We densely profiled microbiome, transcriptome and metabolome signatures from longitudinal IBD cohorts before and after advanced drug therapy initiation and reconstructed metabolic models of the gut microbiome and the host intestine to study host-microbiome metabolic cross-talk in the context of inflammation. We identified concomitant changes in metabolic activity across data layers involving NAD, amino acid, one-carbon and phospholipid metabolism. In particular on the host level, elevated tryptophan catabolism depleted circulating tryptophan, thereby impairing NAD biosynthesis. Reduced host transamination reactions disrupted nitrogen homeostasis and polyamine/glutathione metabolism. The suppressed one-carbon cycle in patient tissues altered phospholipid profiles due to limited choline availability. Simultaneously, microbiome metabolic shifts in NAD, amino acid and polyamine metabolism exacerbated these host metabolic imbalances. Leveraging host and microbe metabolic models, we predicted dietary interventions remodeling the microbiome to restore metabolic homeostasis, suggesting novel therapeutic strategies for IBD.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand the multi - level dysregulation mechanisms of the host - microbe metabolic network in inflammatory bowel disease (IBD). Specifically, the researchers intensively analyzed the gut microbiome, transcriptome, and metabolome characteristics of IBD patients and constructed metabolic models of the host gut and gut microbiota to explore the metabolic interactions between the host and microbes during inflammation. The main objectives of the paper include: 1. **Identify metabolic changes during inflammation**: The researchers aimed to determine the changes in host and microbial metabolic activities during inflammation in IBD patients, especially in terms of NAD, amino acids, one - carbon metabolism, and phospholipid metabolism. 2. **Explore the interactions between host and microbial metabolism**: By integrating multi - layer data (microbiome, transcriptome, and metabolome), the researchers hoped to reveal the complex interactions between the host and microbial metabolic networks, especially how these interactions affect the inflammatory process. 3. **Predict potential treatment strategies**: Based on the metabolic models, the researchers attempted to predict possible dietary interventions to reshape the microbiota and restore metabolic homeostasis, thereby providing new treatment strategies for IBD. ### Main findings 1. **Reduction in NAD metabolism**: The study found that the host's NAD metabolism was significantly reduced during inflammation, which was related to the decrease in niacin production by microbes. 2. **Alteration in amino acid metabolism**: The host's amino acid metabolism was altered in IBD patients. In particular, the enhanced tryptophan metabolism led to a decrease in circulating tryptophan, which in turn affected the biosynthesis of NAD. 3. **Reduction in one - carbon metabolism**: The host's one - carbon metabolism decreased during inflammation, leading to changes in the phospholipid profile, which may be due to the limited availability of choline. 4. **Alteration in microbial metabolism**: Changes in the microbiota in terms of NAD, amino acids, and polyamine metabolism exacerbated the host's metabolic imbalance. 5. **Serum metabolomics verification**: Through serum metabolomics data, the researchers verified the predictions of the metabolic model and confirmed the changes in the levels of multiple metabolites related to inflammation. ### Conclusion By comprehensively analyzing the metabolic activities of the host and microbes, the researchers revealed the multi - level dysregulation mechanisms of the host - microbe metabolic network in IBD and proposed potential dietary intervention strategies to restore metabolic homeostasis, providing new ideas for the treatment of IBD.

Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD

Metabolic modelling reveals broad changes in gut microbial metabolism in inflammatory bowel disease patients with dysbiosis

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Gut microbiome structure and metabolic activity in inflammatory bowel disease

Metabolic network of the gut microbiota in inflammatory bowel disease

Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives

DOP26 Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort

Diet-microbiota-metabolite interaction networks reveal key players in inflammatory bowel disease.

The Involvement of Intestinal Tryptophan Metabolism in Inflammatory Bowel Disease Identified by a Meta-Analysis of the Transcriptome and a Systematic Review of the Metabolome

Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease

Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis

Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

Microenvironmental Factors that Shape Bacterial Metabolites in Inflammatory Bowel Disease

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases

Microbiome and Metabolome Features in Inflammatory Bowel Disease Via Multi-Omics Integration Analyses Across Cohorts

A metabolic constraint in the kynurenine pathway drives mucosal inflammation in IBD

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

Integrated multi-model analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD

Integrated annotation prioritizes metabolites with bioactivity in inflammatory bowel disease

Metabolic Host–Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD)

Gut microbiota-derived metabolites as key actors in inflammatory bowel disease